Mohammad A. Al Sheikhani a and Bnar Sardar Saida b

a Kurdistan Center for Gastrohepatology and Hepatology; Department of Medicine, College of Medicine, University of  Sulaimani. 

b Shar Hospital, Directory of Health, Ministry of Health, Sulaimani, Iraqi Kurdistan, Iraq.

Submitted: 12/2/2017; Accepted: 1/8/2017; Published: 15/8/2017

DOI Link: https://doi.org/10.17656/jsmc.10122



Helicobacter pylori infection has a high global prevalence and carries a significant disease burden. For more than 10 years now, the recommended therapy worldwide for eradication has been a standard triple therapy with amoxicillin, clarithromycine and a proton pump inhibitor. The success of this therapy has been declined in the recent years due to many factors.


To determine the efficacy of the current standard triple anti-Helicobacter pylori treatment in Slemani.

Patients and Methods

This is a prospective study enrolling 62 patients carried out at Shar teaching hospital endoscopy department during a period from January 2015 through January 2016. Patients with gastric and duodenal ulcer underwent biopsy taken from body and antrum of their stomach (one sample from each part), along with stool samples for monoclonal stool antigen testing. They were subjected to standard triple therapy for 2 weeks. After 4 weeks of completion of the treatment they underwent stool antigen test to confirm the eradication.


The eradication rate was 58%. Male gender, smoking, diabetes and non-steroidal anti inflammatory dug use had reduced chance of cure.


The eradication rate was low in our locality for the standard triple therapy. Possibly due to many factors, including rising numbers of antibiotic resistance, smoking, poor compliance and comorbidities like diabetes mellitus.


H. pylori, Triple therapy, Gastric ulcer, Duodenal ulcer.


1. Malfertheiner P, Megraud F, O‘Morain CA et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64.

2. Jafri NS, Hornung CA, Howden CW, et al. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med . 2008 Jun 17;148(12):923-31. Epub 2008 May 19

3. Mégraud F. Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. Gut Microbes. 2013;4:Epub ahead of print.

4. Thung, H. Aramin, V. Vavinskaya, S. Gupta, J. Y. Park, S. E. Crowe, M. A. et all. Review article: the global emergence of Helicobacter pylori antibiotic resistance;Aliment Pharmacol Ther. 2016 Feb; 43(4): 514–533.

5. Su P, Li Y, Li H, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18:274–279.

6. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206–214.

7. De Francesco V, Margiotta M, Zullo A, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother. 2007;59:783–785.

8. Garza E, Guillermo Ignacio, Héctor Jesús , Francisco Javier. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014 Feb 14; 20(6): 1438–1449 .

9. Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211–223.

10. Alsohaibani F, Alashgar H, Alkahtani K, et al. prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection. Saudi J Gastroenterol 2015;21:220-5

11.Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. 2011.

12 Eun Jeong Gong, Sung-Cheol Yun, Hwoon-Yong Jung, et al. Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change? J Korean Med Sci. 2014 May;29(5):704-713. English

13 Shiota S, Rita Reddy, Abeer Alsarraj,et al. Graham, Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans, September 2015 Volume 13, Issue 9, Pages 1616–1624.

14. Thung. Global emergence of Helicobacter pylori antibiotic resistance. Aliment pharmacol Ther 2016; 43: 514-533.

15. J. P. Gisbert; X. Calvet, The Effectiveness of Standard Triple Therapy for Helicobacter pylori Has Not Changed Over the Last Decade, But it is Not Good Enough, ,Aliment Pharmacol Ther. 2011;34(11):1255-1268.

16. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet, 2011 Aug 6;378(9790):507-14.

17. Vakil N, Lanza F, Schwartz H. Seven-day therapy for Helicobacterpylori in the United States. AlimentPharmacol Ther 2004; 20: 99–107.

18. Tursi A, Elisei W, Giorgetti G, et al. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. Panminerva Medica [2014, 56(1):57-61]

19. Namiot DB, Leszczynska K, Namiot Z. Smoking and drinking habits are important predictors of Helicobacter pylori Eradication. Advances in Medical Sciences. 2008, 53(2): 310-15.

20. Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119:217-224

21. Demir M., Gokturk HS, Ozturk NA et al. Clarithromycine resistance and efficacy of Clarithromycine-containing triple eradication therapy for Helicobacter Pylori infection in type 2 diabetes mellitus patients. Southern Medical Journal 2009;102(11):1116-1120.

22. Sargyn M, Oya Uygur Bairamicli, Haluk Sargin et al. Type 2 diabetes mellitus affects eradication rate Helicobacter pylori. World J Gastroenterol, 2003 May 15; 9(5) 1126-1128.

Full Text

 © The Authors, published by University of Sulaimani, College of Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.